Table 1 Correlation between FARP1 expression and clinicopathological factors in gastric cancer patients.
FARP1 expression, n (%) | P value | ||
|---|---|---|---|
Low | High | ||
Patient, n = 91 | 47 (51.6) | 44 (48.4) | |
Age, n = 91 | |||
≤65 | 20 (55.6) | 16 (44.4) | 0.697 |
<65 | 27 (49.1) | 28 (50.9) | |
Gender, n = 91 | |||
Men | 31 (50.0) | 31 (50.0) | 0.814 |
Women | 16 (55.2) | 13 (44.8) | |
Adjuvant chemotherapy, n = 67 | |||
Yes | 20 (51.3) | 19 (48.7) | 0.269 |
No | 19 (67.9) | 9 (32.1) | |
Pathological type, n = 91 | |||
Differentiated | 12 (42.9) | 16 (57.1) | 0.373 |
Undifferentiated | 35 (55.6) | 28 (44.4) | |
T (pathological), n = 91 | |||
pT2 | 9 (60.0) | 6 (40.0) | 0.654 |
pT3 | 23 (52.3) | 21 (47.7) | |
pT4a | 15 (48.4) | 16 (51.6) | |
pT4b | 0 (0.0) | 1 (100.0) | |
N (pathological), n = 91 | |||
pN1 | 19 (82.6) | 4 (17.4) | 0.012 |
pN2 | 7 (43.8) | 9 (56.2) | |
pN3 | 8 (36.4) | 14 (63.6) | |
pN4a | 8 (38.1) | 13 (61.9) | |
pN4b | 5 (55.6) | 4 (44.4) | |
Stage, n = 91 | |||
IB | 8 (80.0) | 2 (20.0) | 0.352 |
IIA | 8 (61.5) | 5 (38.5) | |
IIB | 7 (58.3) | 5 (41.7) | |
IIIA | 6 (37.5) | 10 (62.5) | |
IIIB | 10 (50.0) | 10 (50.0) | |
IIIC | 5 (35.7) | 9 (64.3) | |
IV | 3 (50.0) | 3 (50.0) | |
Lymphatic invasion, n = 91 | |||
ly1 | 14 (77.8) | 4 (22.2) | 0.025 |
ly2 | 16 (57.1) | 12 (42.9) | |
ly3 | 10 (43.5) | 13 (56.5) | |
ly4 | 7 (31.8) | 15 (68.2) | |
Venous invasion, n = 91 | |||
v1 | 7 (41.2) | 10 (58.8) | 0.191 |
v2 | 23 (65.7) | 12 (34.3) | |
v3 | 9 (47.4) | 10 (52.6) | |
v4 | 8 (40.0) | 13 (65.0) | |
Recurrence, n = 82 | |||
Yes | 5 (22.7) | 17 (77.3) | 0.002 |
No | 39 (65.0) | 21 (35.0) | |
Recurrence pattern, n = 20 | |||
Local | 1 (33.3) | 2 (67.7) | 0.886 |
Lymphogenus | 1 (25.0) | 3 (75.0) | |
Hematogenous | 1 (25.0) | 3 (75.0) | |
Peritoneal dissemination | 0 (0.0) | 3 (100.0) | |
Multiple | 1 (20.0) | 4 (80.0) | |
Follow-up lost, n = 7 | 3 (42.9) | 4 (57.1) | 1 |
